Financials

News Ideas Discussions Technicals Seasonals

LASA fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Lasa Supergenerics Ltd. engages in the manufacture of veterinary preparations. It offers veterinary application programming interface products, animal feed ingredients, and reagents for therapeutic use. Its products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Triclabendazole, Rafoxanide, and Ornidazole. The company was founded on March 11, 2016 and is headquartered in Mumbai, India.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

LASA has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company